Risk of Product Obsolescence Due to Technological Innovation
First written in FY2016. 25 of 26 entries say "Restated". Latest entry: FY2025.
2 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「If new technologies that revolutionize testing and treatment methods are developed in the future, the products provided by the Group could become obsolete, leading to a decline in market share and lower selling prices, which could affect the Group's results.」
The risks of product obsolescence due to technological innovation, declining market share, and lower selling prices, together with the response through research and development based on customer needs, continue. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2024-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2023-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2022RestatedAnnual report
「If new technologies that revolutionize testing and treatment methods are developed in the future, the products provided by the Group could become obsolete, leading to a decline in market share and lower selling prices, which could affect the Group's results.」
The risks of product obsolescence due to technological innovation, declining market share, and lower selling prices, together with the response through research and development tailored to customer needs, continue. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2022-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2022-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2021RestatedAnnual report
「If new technologies that revolutionize testing and treatment methods are developed in the future, the products provided by the Group could become obsolete, leading to a decline in market share and lower selling prices, which could affect the Group's results.」
The risk of product obsolescence due to technological innovation and the response policy based on research and development and cooperation within the Group continue. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2020-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2019-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2018RestatedAnnual report
「Technological advances in the medical industry are extremely rapid, and research and development of new products is essential for companies to continue growing. The Group's basic policy is to research, develop, and provide products that meet increasingly diverse and sophisticated market changes and customer needs. However, if new technologies that revolutionize testing and treatment methods are developed in the future, the products provided by the Group could become obsolete, which could affect the Group's results.」
While advancing research and development in response to technological progress, the risk of product obsolescence due to new technologies continues. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2018-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2017-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2017-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of product obsolescence due to technological innovation is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2016First statedAnnual report
「Technological advances in the medical industry are extremely rapid, and research and development of new products is essential for companies to continue growing. The Group's basic policy is to research, develop, and provide products that meet increasingly diverse and sophisticated market changes and customer needs. However, if new technologies that revolutionize testing and treatment methods are developed in the future, the products provided by the Group could become obsolete, which could affect the Group's results.」
While treating research and development as a prerequisite for continued growth, the Group identifies the obsolescence of existing products due to new technologies as a risk.